RanBP2/Nup358 Mediates Sumoylation of STAT1 and Antagonizes Interferon-α-Mediated Antiviral Innate Immunity

• Published in: International journal of molecular sciences Vol. 25; no. 1; p. 299
• Main Authors: Li, Jiawei, Su, Lili, Jiang, Jing, Wang, Yifan E, Ling, Yingying, Qiu, Yi, Yu, Huahui, Huang, Yucong, Wu, Jiangmin, Jiang, Shan, Zhang, Tao, Palazzo, Alexander F, Shen, Qingtang
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 25-12-2023; MDPI
• Subjects: Antibodies; Biological response modifiers; CRISPR; Cytokine storm; Enzymes; Health aspects; Immune response; Infection; Infections; innate immunity; Interferon; Kinases; Localization; Medical research; Medicine, Experimental; MicroRNAs; Mutation; Phosphorylation; Porins; Protein binding; Proteins; RanBP2; STAT1; sumoylation; Transcription factors; Tumor necrosis factor-TNF; viral infection; Viral infections; China; RanBP2; sumoylation; viral infection; innate immunity; interferon; STAT1
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25010299

Type I interferon (IFN-I)-induced signaling plays a critical role in host antiviral innate immune responses. Despite this, the mechanisms that regulate this signaling pathway have yet to be fully elucidated. The nucleoporin Ran Binding Protein 2 (RanBP2) (also known as Nucleoporin 358 KDa, Nup358) has been implicated in a number of cellular processes, including host innate immune signaling pathways, and is known to influence viral infection. In this study, we documented that RanBP2 mediates the sumoylation of signal transducers and activators of transcription 1 (STAT1) and inhibits IFN-α-induced signaling. Specifically, we found that RanBP2-mediated sumoylation inhibits the interaction of STAT1 and Janus kinase 1 (JAK1), as well as the phosphorylation and nuclear accumulation of STAT1 after IFN-α stimulation, thereby antagonizing the IFN-α-mediated antiviral innate immune signaling pathway and promoting viral infection. Our findings not only provide insights into a novel function of RanBP2 in antiviral innate immunity but may also contribute to the development of new antiviral therapeutic strategies.